GlassScriptPhysician profile
Mohamad R Alsibae
NPI 1326230038
$126,658.51
in general payments reported to CMS, 2019-2025
6 companies · $52K in 2025
The $52K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $3,125 · 2021: $7,386 · 2022: $18K · 2023: $4,507 · 2024: $9,568 · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $4,400 · Travel and Lodging: $1,292 · Honoraria: $880 · Food and Beverage: $524 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,513.50 |
| Consulting Fee | $4,400.00 |
| Travel and Lodging | $1,292.15 |
| Honoraria | $880.00 |
| Food and Beverage | $524.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $60,222.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $37,430.07 | 2019-2024 | Ocaliva |
| Abbvie INC. | $25,996.47 | 2019-2022 | |
| Dova Pharmaceuticals | $2,747.50 | 2019 | |
| Genentech USA, INC. | $193.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Alsibae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.